Setmelanotide Side Effects: Safety Signals and Warnings
Setmelanotide safety concerns are compound-specific. The main listed side effects are Skin hyperpigmentation, Injection site reactions, and Nausea. The main warning signals are Only indicated for obesity due to confirmed POMC, PCSK1, or LEPR deficiency - not for general obesity, Genetic testing demonstrating variants in POMC, PCSK1, or LEPR required before prescribing, and Risk of depression and suicidal ideation - monitor patients.
Direct Answer
Setmelanotide (Imcivree) is FDA-approved for chronic weight management in patients with specific genetic obesity syndromes (POMC, PCSK1, or LEPR deficiency). In its approved population, it produces dramatic and clinically meaningful weight loss. Outside this narrow genetic indication, there is no evidence base. It is not a general obesity treatment - but for research into melanocortin pathway obesity, it is the only approved compound in its class.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Weight Loss & Metabolic
- Best for
- MC4R-pathway genetic obesity (POMC/PCSK1/LEPR deficiency), melanocortin pathway obesity research
Reported Side Effects
- Skin hyperpigmentation
- Injection site reactions
- Nausea
- Diarrhea
- Abdominal pain
- Spontaneous penile erection (due to melanocortin activity)
- Depression
Warnings
- Only indicated for obesity due to confirmed POMC, PCSK1, or LEPR deficiency - not for general obesity
- Genetic testing demonstrating variants in POMC, PCSK1, or LEPR required before prescribing
- Risk of depression and suicidal ideation - monitor patients
- Spontaneous erections reported in male patients
- Skin darkening occurs in most patients
- REMS program required due to risk of depression
Known or Plausible Interactions
- No significant drug interactions identified in clinical trials
- Theoretical interaction with other melanocortin-active compounds
Regulatory Context
FDA approved (2020, Imcivree). Prescription required. Available through specialty pharmacy only. REMS program required.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | Weight Loss in Genetic Obesity (Level A), Hunger Reduction (Level A), and Skin Hyperpigmentation (Level A) |
| Primary citation count | 2 |
| Last reviewed | 2026-04-04 |
Related Guides
How to Cite This Page
ExaminePeptides. "Setmelanotide Side Effects: Safety Signals and Warnings." Last reviewed 2026-04-04. https://examinepeptides.com/answers/setmelanotide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.